Patent · US Active

Leukemia diagnostic kit targeting prohibitin gene and diagnostic method using same

US11339421B2 · kind B2 · utility

0Cited by
0References
4Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 21, 2017
Grant dateMay 24, 2022
Priority date
Expiry dateFeb 12, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/166
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

A leukemia diagnostic kit may be an RT-PCR kit enabling expression levels of prohibitin-1 and prohibitin-2 to be checked in a leukemia patient specimen, wherein the accuracy and the reproducibility of leukemia diagnosis of the kit are higher than those of a conventional RT-PCR kit, thereby being useful as a kit for diagnosing leukemia, examining residual lesions and evaluating therapeutic effects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.